The role of JNK in the development of hepatocellular carcinoma

Madhumita Das,¹ David S. Garlick,² Dale L. Greiner,¹ and Roger J. Davis^{1,3,4}

¹Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA;

²Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA;

³Howard Hughes Medical Institute, Worcester, Massachusetts 01605, USA

The cJun NH₂-terminal kinase (JNK) signal transduction pathway has been implicated in the growth of carcinogen-induced hepatocellular carcinoma. However, the mechanism that accounts for JNK-regulated tumor growth is unclear. Here we demonstrate that compound deficiency of the two ubiquitously expressed JNK isoforms (JNK1 and JNK2) in hepatocytes does not prevent hepatocellular carcinoma development. Indeed, JNK deficiency in hepatocytes increased the tumor burden. In contrast, compound JNK deficiency in hepatocytes and nonparenchymal cells reduced both hepatic inflammation and tumorigenesis. These data indicate that JNK plays a dual role in the development of hepatocellular carcinoma. JNK promotes an inflammatory hepatic environment that supports tumor development, but also functions in hepatocytes to reduce tumor development.

[**Keywords:** JNK; partial hepatectomy; hepatocellular carcinoma]

Supplemental material is available for this article.

Received September 3, 2010; revised version accepted February 2, 2011.

The cJun NH₂-terminal kinase (JNK) pathway is implicated in tumor development (Davis 2000). Targets of JNK signaling include members of the activating protein 1 (AP1) transcription factor group (e.g., cJun, JunB, JunD, and related proteins). These transcription factors function within a regulatory network that controls multiple aspects of cellular physiology, including proliferation (Eferl and Wagner 2003). Studies of murine embryo fibroblasts (MEFs) demonstrate that loss of JNK causes major defects in cellular proliferation (Tournier et al. 2000) and AP1-dependent gene expression (Ventura et al. 2003). These effects of JNK are mediated, in part, by the AP1 transcription factor. Indeed, cJun phosphorylation is required for normal serum-stimulated cell growth (Behrens et al. 1999). The JNK signaling pathway therefore represents an important regulatory mechanism that can control growth. Moreover, dysregulated JNK may contribute to tumor development (Davis 2000).

Studies of the role of the JNK and cJun in the liver have confirmed the importance of this signaling pathway in growth regulation. Thus, cJun-deficient mice (Behrens et al. 2002; Stepniak et al. 2006), JNK1-deficient mice (Hui et al. 2008), and mice treated with a JNK inhibitor (Schwabe et al. 2003) exhibit major defects in liver regeneration following partial hepatectomy (PHx). Furthermore, both cJun-deficient mice (Eferl et al. 2003) and

JNK1-deficient mice (Sakurai et al. 2006; Hui et al. 2008) are protected against the development of hepatocellular carcinoma (HCC) following exposure to the carcinogen diethylnitrosamine (DEN). The critical role of JNK in HCC has been confirmed by pharmacological inhibition of JNK and studies of human HCC cells (Hui et al. 2008).

The mechanism of JNK and cJun signaling in the liver that contributes to regeneration and HCC is unclear, but down-regulation of the proliferation inhibitor p21^{CIP1} and up-regulation of the growth promoter cMyc appear to be critical factors (Stepniak et al. 2006; Hui et al. 2008). An alternative mechanism for the contribution of JNK to HCC is represented by the role of compensatory proliferation in hepatic tumor development (Fausto 1999). It has been reported that JNK1 is required for hepatocyte death in the DEN model of HCC (Sakurai et al. 2006). Reduced hepatocyte death in JNK1-deficient mice results in reduced compensatory proliferation and suppression of HCC (Sakurai et al. 2006). These mechanisms are not mutually exclusive, and it is possible that JNK plays multiple roles in HCC, including regulation of cell death and gene expression. Nevertheless, a common theme among these mechanisms is that JNK plays a critical role in hepatocytes that is required for HCC development.

The purpose of this study was to examine the role of JNK in the development of HCC. Specifically, we tested whether JNK in hepatocytes contributes to tumor formation. Previous studies have focused on an analysis of *Jnk1*^{-/-} mice (Sakurai et al. 2006; Hui et al. 2008). Here we report the analysis of mice with tissue-specific deficiency of JNK and mice with compound deficiency of both JNK1 and JNK2. Our analysis demonstrates that

⁴Corresponding author.

E-MAIL roger.davis@umassmed.edu; FAX (508) 856-3210.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1989311>.

Freely available online through the *Genes & Development* Open Access option.

compound JNK deficiency in hepatocytes increases the development of HCC. JNK therefore functions in liver parenchymal cells to reduce tumor development. We show that the protumorigenic effects of JNK on HCC are associated with inflammation and require JNK function in nonparenchymal cells.

Results

Compound JNK deficiency in hepatocytes does not prevent liver regeneration following PHx

PHx causes JNK activation and a robust regeneration response that results in rapid restoration of liver mass (Westwick et al. 1995). It has been reported that *Jnk1*^{-/-} mice exhibit a defect in the regeneration response to PHx (Hui et al. 2008). In initial studies, we compared hepatic regeneration in control mice, *Jnk1*^{-/-} mice, and *Jnk2*^{-/-} mice following PHx. This analysis demonstrated similar hepatic regeneration in control and *Jnk2*^{-/-} mice, but hepatic regeneration was suppressed in *Jnk1*^{-/-} mice

(Supplemental Fig. S1). These data indicate that JNK1 may play an important role in hepatocyte proliferation (Hui et al. 2008).

The *Jnk1* and *Jnk2* genes are both expressed in hepatocytes (Davis 2000). Consequently, the reduced hepatic regeneration detected in *Jnk1*^{-/-} mice (Supplemental Fig. S1) is not caused by loss of total JNK in hepatocytes. These considerations indicated that studies of hepatic regeneration in mice with compound ablation of *Jnk1* plus *Jnk2* are required. We employed a conditional gene ablation strategy using *Alb-Cre* transgenic mice to create animals with compound deficiency of JNK1 plus JNK2 in hepatocytes (Das et al. 2009). Control H^{WT} mice (*Alb-Cre*^{+/+}) and JNK-deficient H^{ΔJNK} mice (*Alb-Cre*^{+/+} *Jnk1*^{LoxP/LoxP} *Jnk2*^{-/-}) were examined following PHx or a sham surgical procedure (Fig. 1A).

Biochemical analysis of the liver of H^{WT} and H^{ΔJNK} mice at 48 h post-PHx demonstrated that JNK deficiency did not significantly change the expression of *cJun*, *JunB*, or *Cyclin D1* mRNA, but a modest reduction in *JunD*

Figure 1. JNK deficiency in hepatocytes does not prevent liver regeneration after PHx. (A) Control mice (H^{WT} mice: *Alb-Cre*^{+/+}) and JNK-deficient mice (H^{ΔJNK} mice: *Alb-Cre*^{+/+} *Jnk1*^{LoxP/LoxP} *Jnk2*^{-/-}) were subjected to two-thirds PHx or a sham procedure. The mice were injected (i.p.) with 100 μg/g BrdU (dissolved in saline) at 2 h prior to euthanasia. Representative sections of liver from mice at 48 h post-surgery were stained with H&E (top panels) and an antibody to BrdU (bottom panels). (B) The liver/body weight ratio was calculated and expressed as the mean percentage ± SD (*n* = 6 mice) in H^{WT} and H^{ΔJNK} mice. No statistically significant differences between H^{WT} and H^{ΔJNK} mice were detected. (C) The percentage of BrdU-positive hepatocytes in H^{WT} and H^{ΔJNK} mice (mean ± SD; *n* = 8 mice) is presented. Statistically significant differences between H^{WT} and H^{ΔJNK} mice are indicated. (*) *P* < 0.05; (**) *P* < 0.001. (D) The percentage of hepatocyte mitotic figures detected in H&E-stained sections of liver from H^{WT} and H^{ΔJNK} mice (mean ± SD; *n* = 8 mice) is presented. Statistically significant differences between H^{WT} and H^{ΔJNK} mice are indicated. (*) *P* < 0.05.

mRNA expression was detected in the liver of $H^{\Delta JNK}$ mice compared with H^{WT} mice (Supplemental Fig. S2A). These changes were associated with reduced activation of JNK and reduced phosphorylation of cJun in the liver of $H^{\Delta JNK}$ mice compared with H^{WT} mice (Supplemental Fig. S2B). These observations are consistent with ablation of the JNK signaling pathway in the hepatocytes of $H^{\Delta JNK}$ mice. We detected no statistically significant changes in activation of AKT or the ERK and p38 MAPKs in the JNK-deficient liver compared with control liver (Supplemental Fig. S2B).

Measurement of hepatic mass demonstrated that compound deficiency of JNK1 plus JNK2 in hepatocytes caused no significant change in regeneration (Fig. 1B). To confirm this conclusion, we examined hepatocyte proliferation by measuring the incorporation of bromodeoxyuridine (BrdU) (Fig. 1A). This analysis demonstrated increased BrdU incorporation at 48 h post-PHx in both H^{WT} and $H^{\Delta JNK}$ mice, but the amount of BrdU incorporation was reduced in $H^{\Delta JNK}$ mice compared with H^{WT} mice (Fig. 1C). This reduction in BrdU incorporation is consistent with the reduced number of mitotic figures detected in hepatocytes of $H^{\Delta JNK}$ mice compared with H^{WT} mice at 48 h post-PHx (Fig. 1D). However, a time-course analysis demonstrated that the overall hepatic proliferation in H^{WT} and $H^{\Delta JNK}$ mice following PHx was similar (Fig. 1C,D). These data demonstrate that compound JNK deficiency does not prevent hepatic regeneration following PHx.

The discovery that mice with compound JNK deficiency in hepatocytes were capable of hepatic regeneration following PHx was unexpected for two reasons. First, hepatic regeneration is strongly reduced in $Jnk1^{-/-}$ mice

(Supplemental Fig. S1; Hui et al. 2008). Second, studies of $Jnk1^{-/-} Jnk2^{-/-}$ primary MEFs demonstrate that these JNK-deficient cells exhibit severe defects in proliferation, including early senescence (Tournier et al. 2000; Das et al. 2007). Compound JNK deficiency was therefore anticipated to similarly cause growth retardation in other cell types, including hepatocytes. We therefore sought to confirm that liver regeneration following PHx is JNK-independent using a different mouse model with compound hepatic JNK deficiency (Supplemental Fig. S3). Together, these data confirm the conclusion that hepatic regeneration following PHx occurs in mice with deficiency of both JNK1 and JNK2 in the liver (Fig. 1; Supplemental Fig. S3). JNK is therefore not essential for hepatic regeneration.

JNK deficiency in hepatocytes promotes HCC

The conclusion that JNK is not essential for hepatic regeneration led us to question whether JNK is required for hepatocyte proliferation in the context of HCC. We therefore tested whether JNK in hepatocytes is required for HCC development by treating H^{WT} and $H^{\Delta JNK}$ mice with the carcinogen DEN. Previous reports indicate that DEN-induced HCC is markedly reduced in $Jnk1^{-/-}$ mice (Sakurai et al. 2006; Hui et al. 2008). In contrast, we found that $H^{\Delta JNK}$ mice developed HCC following exposure to DEN (Fig. 2A; Supplemental Fig. S4). Indeed, the tumor size in $H^{\Delta JNK}$ mice was significantly greater than in H^{WT} mice (Fig. 2B). However, no significant difference in tumor incidence or the number of tumor nodules between H^{WT} and $H^{\Delta JNK}$ mice was detected (Fig. 2C). This effect of JNK deficiency to increase HCC was associated with increased hepatic expression of cJun (Supplemental

Figure 2. Effect of hepatocyte-specific JNK deficiency on HCC. (A) DEN-induced HCC in control mice (H^{WT} mice: $Alb-Cre^{+/+}$) and JNK-deficient mice ($H^{\Delta JNK}$ mice: $Alb-Cre^{+/+} Jnk1^{LoxP/LoxP} Jnk2^{-/-}$) at 38 wk of age. (B) The maximum diameter of individual tumor nodules (right panel) and the mean $\pm$ SD ($n = 13$) width of the tumor nodules (left panel) are presented. Statistically significant differences between H^{WT} and $H^{\Delta JNK}$ mice are indicated. (*) $P < 0.05$. (C) The tumor incidence (left panel) and the number of tumors per mouse (right panel) were examined ($n = 14$). No statistically significant differences between H^{WT} and $H^{\Delta JNK}$ mice were detected. (D) Representative sections of liver from mice treated without DEN (control) and with DEN (tumor) stained with H&E are presented. (E) Immunoblot analysis of tumors isolated from H^{WT} mice and $H^{\Delta JNK}$ mice was performed by probing with antibodies to JNK and α -Tubulin (Tub.). (F) Kaplan-Meier analysis of the survival of H^{WT} mice and $H^{\Delta JNK}$ mice ($n = 10$) treated with DEN is presented. No statistically significant difference between the survival or mortality of H^{WT} mice and $H^{\Delta JNK}$ mice was detected (log-rank test; $P = 0.055$).

Fig. S5A). Histological analysis of hepatic sections demonstrated the presence of lesions ranging from adenoma to carcinoma in H^{WT} mice, but primarily carcinoma in $H^{\Delta JNK}$ mice (Fig. 2D; Supplemental Figs. S6, S7). Immunoblot analysis demonstrated that $H^{\Delta JNK}$ tumors were JNK deficient (Fig. 2E). Together, these data indicate that JNK in hepatocytes acts as to reduce tumor development in this model of HCC. However, Kaplan-Meier analysis demonstrated that the increased tumor burden in the $H^{\Delta JNK}$ mice did not cause a statistically significant ($P = 0.055$) change in survival compared with H^{WT} mice (Fig. 2F).

JNK deficiency can prevent HCC development

The finding that JNK in hepatocytes acts to reduce HCC (Fig. 2) was not anticipated because studies of *Jnk1*^{-/-} mice (but not *Jnk2*^{-/-} mice) have indicated that JNK plays a critical role in HCC development (Sakurai et al. 2006; Hui et al. 2008). Together, these findings suggest that JNK may both inhibit and promote tumor formation during DEN-induced HCC development. The protumorigenic role of JNK does not require the function of JNK in hepatocytes (Fig. 2), but may involve functions of JNK in nonparenchymal cells. To test this hypothesis, we examined DEN-induced HCC development in mice with compound JNK deficiency using *Mx-1-Cre* mice and conditional gene ablation in hepatocytes and nonparenchymal cells (Das et al. 2009).

Control Mx^{WT} mice (*Mx-1-Cre*^{+/-}) and JNK-deficient $Mx^{\Delta JNK}$ mice (*Mx-1-Cre*^{+/-} *Jnk1*^{LoxP/LoxP} *Jnk2*^{-/-}) were tested for HCC development. We found that HCC was strongly suppressed in $Mx^{\Delta JNK}$ mice compared with Mx^{WT}

mice (Fig. 3A; Supplemental Fig. S4). The tumor size in $Mx^{\Delta JNK}$ mice was significantly smaller than in Mx^{WT} mice (Fig. 3B). Moreover, both the tumor incidence and the number of tumor nodules were reduced in $Mx^{\Delta JNK}$ mice compared with Mx^{WT} mice (Fig. 3C). This effect of JNK deficiency to suppress HCC was associated with markedly reduced hepatic expression of cJun (Supplemental Fig. S5B). Histological analysis of hepatic tissue sections demonstrated lesions ranging from adenoma to carcinoma in Mx^{WT} mice, but primarily only localized adenoma were detected in $Mx^{\Delta JNK}$ mice (Fig. 3D; Supplemental Figs. S7, S8). Immunoblot analysis demonstrated that $Mx^{\Delta JNK}$ tumors were JNK-deficient (Fig. 3E). Kaplan-Meier analysis demonstrated that the reduced tumor burden in $Mx^{\Delta JNK}$ mice caused significantly increased survival ($P = 0.017$) compared with Mx^{WT} mice (Fig. 3F). Together, these data demonstrate that JNK can play a protumorigenic role in HCC development. This protumorigenic role does not require JNK in hepatocytes (Fig. 2), but does require JNK in nonparenchymal cells (Fig. 3).

JNK regulation of HCC proliferation mediated by *p21*^{CIP1} and *cMyc*

JNK-mediated transcriptional down-regulation of the growth inhibitor *p21*^{CIP1} and up-regulation of the growth promoter *cMyc* have been implicated as critical steps during HCC development (Hui et al. 2008). We therefore examined *p21*^{CIP1} and *cMyc* expression in the liver of mice with compound deficiency of JNK1 plus JNK2 (Fig. 4). We found that *p21*^{CIP1} expression was significantly increased in DEN-treated JNK-deficient mice ($H^{\Delta JNK}$ and

Figure 3. Effect of hepatic JNK deficiency on HCC. (A) DEN-induced HCC in control mice (Mx^{WT} mice: *Mx1-Cre*^{+/-}) and JNK-deficient mice ($Mx^{\Delta JNK}$ mice: *Mx1-Cre*^{+/-} *Jnk1*^{LoxP/LoxP} *Jnk2*^{-/-}) at 38 wk of age. The JNK-deficient mice lack expression of JNK1 plus JNK2 in both hepatocytes and nonparenchymal hepatic cells. (B) The maximum diameter of individual tumor nodules (right panel) and the mean $\pm$ SD ($n = 13$) width of the tumor nodules (left panel) are presented. Statistically significant differences between Mx^{WT} and $Mx^{\Delta JNK}$ mice are indicated. (*) $P < 0.05$; (**) $P < 0.01$. (C) The tumor incidence (left panel) and the number of tumors per mouse (right panel) were examined ($n = 16$). Statistically significant differences between Mx^{WT} and $Mx^{\Delta JNK}$ mice are indicated. (*) $P < 0.05$. (D) Representative sections of liver from mice treated without DEN (control) and with DEN (tumor) stained with H&E are presented. (E) Immunoblot analysis of tumors isolated from Mx^{WT} mice and $Mx^{\Delta JNK}$ mice was performed by probing with antibodies to JNK and α -Tubulin (Tub.). (F) Kaplan-Meier analysis of the survival of Mx^{WT} mice and $Mx^{\Delta JNK}$ mice ($n = 11$) treated with DEN is presented. The survival of Mx^{WT} mice was significantly shorter than $Mx^{\Delta JNK}$ mice (log-rank test; $P = 0.017$).

ysis of the survival of Mx^{WT} mice and $Mx^{\Delta JNK}$ mice ($n = 11$) treated with DEN is presented. The survival of Mx^{WT} mice was significantly shorter than $Mx^{\Delta JNK}$ mice (log-rank test; $P = 0.017$).

Figure 4. Effect of JNK deficiency on p21CIP1 and cMyc expression in HCC. Mice were treated without (Con) or with DEN and euthanized at 38 wk of age. The expression of p21^{CIP1}, cMyc, and Cyclin D1 mRNA was examined by RT-PCR using TaqMan assays. The data presented are normalized for the amount of *Gapdh* mRNA in each sample and represent the mean $\pm$ SD ($n = 5$). Statistically significant differences are indicated. (*) $P < 0.05$. (A) Control mice (H^{WT}) and mice with JNK deficiency in hepatocytes (H^{ΔJNK}). (B) Control mice (Mx^{WT}) and mice with JNK deficiency in hepatocytes and nonparenchymal cells (Mx^{ΔJNK}).

Mx^{ΔJNK}) compared with DEN-treated control mice (H^{WT} and Mx^{WT}) (Fig. 4). Since HCC is increased in H^{ΔJNK} mice (Fig. 2) and decreased in Mx^{ΔJNK} mice (Fig. 3), these data demonstrate no correlation between p21^{CIP1} expression and HCC development in compound JNK-deficient mice. In contrast, an association between JNK, expression of cMyc, and HCC development was detected. No significant difference between cMyc expression between tumors in mice with (H^{ΔJNK}) and without (H^{WT}) compound JNK deficiency in hepatocytes was observed (Fig. 4A). However, cMyc expression in tumors of mice with compound JNK deficiency in hepatocytes plus nonparenchymal cells (Mx^{ΔJNK}) was strongly reduced compared with tumors of control (Mx^{WT}) mice (Fig. 4B). This downregulation of cMyc expression (Fig. 4B) correlates with markedly decreased expression of Cyclin D1 (Fig. 4B) and decreased tumor formation (Fig. 3). Together, these data support a potential role for JNK-regulated expression of cMyc, but not p21^{CIP1}, during HCC development.

JNK regulates compensatory proliferation during HCC development

It is established that compensatory hepatocyte proliferation plays a major role in the development of HCC (Fausto 1999). This form of hepatocyte proliferation rep-

resents a regenerative response to hepatocyte death that is associated with inflammation (Grivennikov et al. 2010). We therefore examined hepatocyte proliferation and death in control mice (H^{WT} and Mx^{WT}) and mice with compound deficiency of JNK1 plus JNK2 (H^{ΔJNK} and Mx^{ΔJNK}) following treatment with DEN. Sections of liver tumors were stained for the proliferation marker PCNA (Fig. 5A,B) and for cell death using the TUNEL assay (Fig. 5C,D). We also examined caspase activation by immunoblot analysis of Caspase 3 processing to the activated form (Supplemental Fig. S9). Studies of mice with hepatocyte-specific compound JNK deficiency (H^{ΔJNK} mice) demonstrated increased cell death and increased proliferation compared with control H^{WT} mice (Fig. 5A,C; Supplemental Fig. S9). In contrast, compound deficiency of JNK in hepatocytes plus nonparenchymal cells (Mx^{ΔJNK} mice) caused both reduced cell death and reduced proliferation compared with control Mx^{WT} mice (Fig. 5B,D; Supplemental Fig. S9). These data suggest that decreased compensatory proliferation may account for the reduction in tumor growth caused by JNK in hepatocytes, and that increased compensatory proliferation may account for the protumorigenic activity of JNK in nonparenchymal cells.

JNK regulates the expression of hepatic cytokines

The compensatory proliferation caused by hepatocyte death (Fausto 1999) may be mediated by the release of IL1 α by necrotic cells (Chen et al. 2007; Sakurai et al. 2008) and the subsequent expression of protumorigenic IL6 (and also TNF α in obese mice) by hepatic innate immune cells (Naugler et al. 2007; Park et al. 2010). Indeed, HCC development in mice can be suppressed by ablation of the *Il6* and *Tnf α* genes (Naugler et al. 2007; Park et al. 2010). We therefore examined the expression of inflammatory cytokines in control and JNK-deficient mice (Fig. 6). Studies of mice with compound deficiency of JNK1 plus JNK2 in hepatocytes (H^{ΔJNK} mice) demonstrated that JNK deficiency caused increased hepatic expression of *Il1 α* , *Il1 β* , *Il6*, and *Tgf β 1* mRNA (Fig. 6A; Supplemental Fig. S10). In contrast, studies of mice with compound deficiency of JNK1 and JNK2 in hepatocytes plus nonparenchymal cells (Mx^{ΔJNK} mice) demonstrated that JNK deficiency caused decreased expression of *Il1 α* , *Il1 β* , *Il6*, *Tgf β 1*, and *Tnf α* mRNA (Fig. 6B; Supplemental Fig. S10).

Together, these data indicate that JNK deficiency in hepatocytes (H^{ΔJNK} mice) causes increased cell death (Fig. 5C; Supplemental Fig. S9), increased expression of inflammatory cytokines (Figs. 6A; Supplemental Fig. S10), and increased compensatory hepatocyte proliferation (Fig. 5A). However, JNK deficiency in hepatocytes plus nonparenchymal cells (Mx^{ΔJNK} mice) causes decreased cell death (Fig. 5D; Supplemental Fig. S9), decreased expression of inflammatory cytokines (Figs. 6B; Supplemental Fig. S10), and decreased compensatory hepatocyte proliferation (Fig. 5B). The primary actions of JNK disrupted in H^{ΔJNK} mice may reflect a role for JNK in cell survival (Lamb et al. 2003) and thus decreased compensatory proliferation. The primary actions of JNK disrupted in

Figure 5. Effect of JNK deficiency on hepatocyte death and compensatory proliferation. (A–D) Control mice (H^{WT} and Mx^{WT}) and JNK-deficient (ΔJNK) mice ($H^{\Delta JNK}$ and $Mx^{\Delta JNK}$) were treated with DEN. Hepatic tissue sections of mice (age 38 wk) were examined by staining with an antibody to the proliferation marker PCNA (A,B) or by TUNEL assay (C,D). DNA was stained with DAPI. Quantitation of triplicate independent samples demonstrated that $29.0\% \pm 1.1\%$ of H^{WT} and $49.9\% \pm 7.2\%$ of $H^{\Delta JNK}$ nuclei were positive for PCNA ($P < 0.05$), $61.1\% \pm 12.5\%$ of Mx^{WT} and $17.4\% \pm 1.4\%$ of $Mx^{\Delta JNK}$ nuclei were positive for PCNA ($P < 0.05$), $2.5\% \pm 1.2\%$ of H^{WT} and $32.4\% \pm 6.1\%$ of $H^{\Delta JNK}$ nuclei were TUNEL-positive ($P < 0.01$), and $44.2\% \pm 6.6\%$ of Mx^{WT} and $10.7\% \pm 2.3\%$ of $Mx^{\Delta JNK}$ nuclei were TUNEL-positive ($P < 0.01$).

$Mx^{\Delta JNK}$ mice may be expression of the protumorigenic cytokines IL6 and TNF α (Sabio et al. 2008; Das et al. 2009).

The role of IL6 in JNK-regulated development of HCC

It is established that IL6 plays a key role in hepatocyte proliferation (Cressman et al. 1996), and that IL6 is critically required for DEN-induced HCC (Naugler et al. 2007). We therefore examined the hepatic IL6 signaling pathway in mice with compound JNK deficiency. Treatment of control mice with DEN caused an increase in hepatic *Il6* mRNA and IL6 protein in the blood (Fig. 6). The *Socs3* gene is a target of IL6-stimulated STAT3 signaling in the liver. Treatment of mice with DEN caused increased *Socs3* mRNA expression (Fig. 6). This DEN-induced increase in *Socs3* gene expression was suppressed in $Mx^{\Delta JNK}$ mice (Fig. 6B) and potentiated in $H^{\Delta JNK}$ mice (Fig. 6A). These data are consistent with the increased HCC and hepatic IL6 expression in $H^{\Delta JNK}$ mice (Figs. 2, 6A) and reduced HCC and hepatic IL6 expression in $Mx^{\Delta JNK}$ mice (Figs. 3, 6B).

The *miR-21* gene has been identified as a target of inflammatory signaling pathways, including IL6 (Jazbutyte and Thum 2010). Indeed, treatment of mice with IL6 caused increased hepatic expression of *miR-21* (Supplemental Fig. S11), and it is established that IL6-induced *miR-21* expression is mediated by two conserved STAT3-binding sites in the *miR-21* promoter (Loffler et al. 2007). The expression of *miR-21* in the liver is increased during HCC development (Kutay et al. 2006; Meng et al. 2007; Connolly et al. 2008; Jiang et al. 2008), and studies using a knockdown approach demonstrate that *miR-21* contributes to HCC proliferation (Connolly et al. 2008). These data establish that *miR-21* plays an important role in HCC development.

We examined the effect of JNK deficiency on hepatic expression of *miR-21*. Control studies demonstrated that DEN caused increased expression of *miR-21* (Supplemental Fig. S12). Hepatocyte-specific JNK deficiency ($H^{\Delta JNK}$ mice) caused increased *miR-21* expression compared with control (H^{WT}) mice following treatment with DEN (Supplemental Fig. S13A). In contrast, DEN-treated mice with JNK deficiency in hepatocytes and nonparenchymal cells ($Mx^{\Delta JNK}$) expressed reduced *miR-21* compared with control (Mx^{WT}) DEN-treated mice (Supplemental Fig. S13A). These effects of JNK deficiency on *miR-21* expression are consistent with the observed increase ($H^{\Delta JNK}$) and decrease ($Mx^{\Delta JNK}$) in the expression of hepatic IL6 (and other inflammatory cytokines) following DEN treatment (Fig. 6; Supplemental Fig. S10).

Targets of *miR-21* include repressors of the AKT (*Pten*) and receptor tyrosine kinase (*Sprouty*) signaling pathways (Cabrita and Christofori 2008). We therefore examined *Pten* and *Sprouty* expression in DEN-treated control (Mx^{WT}) mice and JNK-deficient ($Mx^{\Delta JNK}$) mice. JNK deficiency did not change the expression of *Pten* or *Sprouty* mRNA (Supplemental Fig. S13C,D). Similarly, JNK deficiency did not cause altered expression of PTEN protein (Supplemental Fig. S13D). In contrast, JNK deficiency caused increased expression of Sprouty protein (Supplemental Fig. S13C). To test whether this increased expression of Sprouty is functionally relevant, we examined signaling pathways downstream from activated receptor tyrosine kinases, including AKT and ERK. We found that increased expression of the negative regulator Sprouty in JNK-deficient ($Mx^{\Delta JNK}$) mice was associated with reduced AKT and ERK activity (Supplemental Fig. S13B). These data suggest that Sprouty (Supplemental Fig. S13C) may be a relevant target of the *miR-21* pathway that is required for HCC development (Connolly et al. 2008).

Das et al.

Figure 6. Effect of JNK deficiency on the expression of hepatic cytokines. (A,B) H^{WT} and H^{ΔJNK} mice (A) or Mx^{WT} and Mx^{ΔJNK} mice (B) were treated without (Con) or with DEN and euthanized at 38 wk of age. The blood concentration of IL6 was measured by ELISA and is presented as the mean $\pm$ SD ($n = 7$). Total RNA was isolated from the liver, and the expression of *Il1α*, *Il1β*, *Il6*, *Socs3*, and *Tnfα* mRNA was examined by RT-PCR using TaqMan assays. The data presented are normalized for the amount of *Gapdh* mRNA in each sample and represent the mean $\pm$ SD ($n = 5$). Statistically significant differences between the control and JNK-deficient mice are indicated ($P < 0.05$).

Discussion

The role of JNK in proliferation is cell type-dependent

It is established that JNK is critically required for the proliferation of primary MEFs (Davis 2000). Compound mutant *Jnk1*^{-/-} *Jnk2*^{-/-} MEFs exhibit a severe growth retardation phenotype (Tournier et al. 2000) and premature senescence (Das et al. 2007). The rapid senescence of primary *Jnk1*^{-/-} *Jnk2*^{-/-} MEFs is mediated by increased expression of the *Trp53* tumor suppressor (Das et al. 2007). This engagement of p53-dependent senescence in primary *Jnk1*^{-/-} *Jnk2*^{-/-} MEFs (Das et al. 2007) is similar to *cJun*^{-/-} MEFs (Schreiber et al. 1999). Indeed, reduced

expression of *cJun* by *Jnk1*^{-/-} *Jnk2*^{-/-} MEFs may contribute to the early senescence phenotype (Ventura et al. 2003). These observations indicate that JNK may have a general role in the proliferation of many cell types. Reports that JNK1 plays an essential role in both hepatic regeneration following PHx (Hui et al. 2008) and DEN-induced HCC (Sakurai et al. 2006; Hui et al. 2008) are consistent with this conclusion.

The finding that compound JNK deficiency does not prevent hepatocyte proliferation was unexpected (Figs. 1, 2; Supplemental Fig. S3). The simplest explanation for these data is that JNK is not required for proliferation of hepatocytes (Fig. 1; Supplemental Fig. S3), but JNK is

selectively required to prevent *Trp53*-dependent senescence of MEFs (Das et al. 2007). Cell type-specific responses to JNK deficiency may reflect differences in the requirement of JNK for the expression of cJun, a repressor of the *Trp53* promoter (Schreiber et al. 1999). Compound JNK deficiency in MEFs causes down-regulation of *cJun* expression (Ventura et al. 2003). In contrast, compound JNK deficiency in hepatocytes did not cause significantly decreased *cJun* expression (Supplemental Fig. S2A). The failure of JNK deficiency to down-regulate cJun expression in hepatocytes may reflect signaling pathway redundancy, including roles of JNK in AP1-dependent cJun expression (Ventura et al. 2003) and p38 MAPK in MEK2-dependent cJun expression (Han et al. 1997). Indeed, it is intriguing that the p38 MAPK pathway in hepatocytes is constitutively activated and subject to metabolic regulation (Mendelson et al. 1996), but p38 MAPK is stress-inducible from a low basal activity in MEFs (Raingeaud et al. 1995). The p38 MAPK pathway may therefore act redundantly with JNK to regulate cJun expression in hepatocytes, but the p38 MAPK pathway may not compensate for JNK deficiency in MEFs. Cross-talk, partially redundant signaling, and partially antagonistic signaling by the JNK and p38 MAPK pathways may therefore contribute to the tissue-specific effects of JNK on proliferation (Wagner and Nebreda 2009).

The role of JNK in liver regeneration

The function of JNK in hepatocytes and nonparenchymal cells of the liver is not required for hepatic regeneration following PHx (Fig. 1; Supplemental Fig. S3). Nevertheless, liver regeneration is reduced in *Jnk1*^{-/-} mice (Supplemental Fig. S1; Hui et al. 2008). The mechanism that accounts for this phenotype of *Jnk1*^{-/-} mice is unclear. The simplest hypothesis is that JNK1 plays a critical role in a nonhepatic tissue, and that this JNK1-dependent function is disrupted in *Jnk1*^{-/-} mice. The identity of the relevant tissue that mediates JNK1-dependent hepatic regeneration has not been established. One possibility is represented by the hypothalamus, a region of the brain that strongly influences liver regeneration (Kiba 2002). This possibility is consistent with the discovery that the major metabolic phenotypes of *Jnk1*^{-/-} mice are largely accounted for by the effects of JNK1 deficiency in the hypothalamus, rather than in peripheral tissues (Belgardt et al. 2010; Sabio et al. 2010). A goal for further studies will be to identify the specific tissue that accounts for the required role of JNK1 for hepatic regeneration. This role of JNK1 contrasts with the absence of a requirement for hepatic JNK during liver regeneration following PHx (Fig. 1; Supplemental Fig. S3).

The role of JNK in the promotion of HCC

It is established that JNK plays a key role in the development of DEN-induced HCC (Sakurai et al. 2006; Hui et al. 2008). Two mechanisms have been reported to account for JNK-mediated protumorigenic activity. First, JNK1 may be required for down-regulation of *p21*^{CIP1}

expression and up-regulation of cMyc expression (Hui et al. 2008). Our analysis demonstrates that *p21*^{CIP1} expression does not correlate with tumorigenic potential in studies of HCC development in compound JNK-deficient mice (*H*^{ΔJNK} and *Mx*^{ΔJNK}) (Fig. 4). In contrast, expression of cMyc (Fig. 4) correlates with the tumor burden in *H*^{ΔJNK} and *Mx*^{ΔJNK} mice (Figs. 2, 3). These data are consistent with a role for cMyc in JNK-dependent formation of HCC (Hui et al. 2008).

A second proposed mechanism is that JNK1 causes hepatocyte death (Sakurai et al. 2006), resulting in compensatory proliferation that contributes to the development of HCC (Fausto 1999). However, compound deficiency of JNK1 and JNK2 in hepatocytes (*H*^{ΔJNK} mice) does not inhibit hepatocyte death following treatment with DEN (Fig. 5C; Supplemental Fig. S9). These data demonstrate that JNK-mediated hepatocyte death does not contribute to compensatory proliferation and HCC. This analysis indicates that another mechanism must account for the protumorigenic effects of JNK on HCC development.

The observation that compound JNK deficiency in hepatocytes (*H*^{ΔJNK} mice) does not reduce DEN-induced HCC (Fig. 2), but compound JNK deficiency in hepatocytes plus nonparenchymal cells (*Mx*^{ΔJNK} mice) does reduce DEN-induced HCC (Fig. 3), provides important insight into the mechanism of JNK-promoted HCC development. These findings indicate that the protumorigenic function of JNK may be localized to nonparenchymal cells, rather than hepatocytes. Indeed, functions of nonparenchymal cells are implicated in HCC development (Maeda et al. 2005; Grivennikov et al. 2010). Specifically, the release of IL1α by necrotic cells (Chen et al. 2007; Sakurai et al. 2008), and the subsequent expression of the protumorigenic cytokine IL6 (and also TNFα in obese mice) by hepatic innate immune cells, including Kupffer cells (Naugler et al. 2007; Park et al. 2010), may drive compensatory hepatocyte proliferation and, subsequently, HCC (Fig. 7). It is therefore significant that compound JNK deficiency in *Mx*^{ΔJNK} mice, but not *H*^{ΔJNK} mice, causes markedly decreased expression of IL6 and TNFα (Fig. 6). These data are consistent with the conclusion that JNK is required for the expression of the protumorigenic cytokines IL6 and TNFα by hepatic innate immune cells during the development of HCC (Fig. 6B). Thus, the protumorigenic activity of JNK may be mediated by a role for JNK in nonparenchymal cells (Fig. 3) in the creation of an inflammatory environment that supports HCC development (Grivennikov et al. 2010). The previously described genetic interactions between *Jnk1* and *p21*^{CIP1} (Hui et al. 2008) may therefore reflect an inhibitory action of *p21*^{CIP1} on hepatic innate immune cells, rather than hepatocytes. Studies using mice with tissue-specific *p21*^{CIP1} deficiency will be required to resolve this question.

The role of JNK in hepatocytes during HCC development

Studies of mice with compound deficiency of JNK1 plus JNK2 demonstrate that cell death and compensatory

Das et al.

Figure 7. JNK functions in hepatocytes to reduce HCC development and in nonparenchymal cells to promote HCC development. JNK in nonparenchymal cells functions to promote HCC development by providing an inflammatory environment that supports HCC, including the expression of the protumorigenic cytokines IL6 and TNF α that contribute to compensatory hepatocyte proliferation. However, JNK in hepatocytes functions to reduce HCC development by promoting hepatocyte survival, therefore decreasing IL1 α release by necrotic hepatocytes and the activation of hepatic innate immune cells, including Kupffer cells, that express the protumorigenic cytokine IL6.

proliferation are key targets of JNK function in HCC (Fig. 5). Specifically, we find that compound JNK deficiency in hepatocytes causes increased hepatocyte death and, consequently, increased compensatory proliferation and HCC development (Figs. 2, 5). The increased death caused by compound JNK deficiency is consistent with previous studies that demonstrate a role for JNK in cell survival (Kuan et al. 1999; Lamb et al. 2003) and the presence of JNK-independent pathways that can mediate hepatocyte death (Das et al. 2009). Although the cell type of HCC origin is unclear (Mishra et al. 2009), tumors detected using *Albumin-Cre* transgenic mouse models of DEN-induced HCC demonstrate efficient ablation of *floxed* genes in tumor cells (Fig. 2E; Maeda et al. 2005). These data suggest that JNK in hepatic parenchymal cells functions to reduce tumor development in the DEN model of HCC. This effect of JNK to influence hepatocyte death, compensatory proliferation, and HCC development (Figs. 2, 5) is similar to the reported effects of hepatocyte-specific deficiency of the NF- κ B activator IKK β (Maeda et al. 2005). Together, these data are consistent with the proposed role of compensatory proliferation in hepatic tumor development (Fausto 1999).

Conclusions

The results of this study demonstrate that JNK plays a complex role in the development of HCC. JNK is required for HCC development because it functions in nonparenchymal cells to cause expression of protumorigenic cytokines, including IL6 and TNF α . In contrast, JNK in hepatocytes reduces tumor development by decreasing hepatocyte death and compensatory proliferation. It is likely that previous studies using mice with whole-body knockout of *Jnk1* or *Jnk2* reflect a composite phenotype derived from the cell type-specific functions of JNK in hepatocytes and nonparenchymal cells.

We conclude that JNK both promotes and inhibits tumor development in the DEN model of HCC. This

conclusion has implications for the more general role of JNK in cancer. Both tumor promotion and inhibition by JNK may contribute to cancer development (Davis 2000; Whitmarsh and Davis 2007). This complicates the analysis of JNK pathway mutations that have been identified in human cancer (Greenman et al. 2007; Kan et al. 2010). Moreover, this dual role of JNK should be considered in the context of the potential use of JNK as a therapeutic target for drug development and the treatment of human cancer.

Materials and methods

Mice

We previously described *Jnk1^{LoxP/LoxP}* mice (Das et al. 2009) and *Jnk2^{-/-}* mice (Yang et al. 1998). B6.Cg-Tg[Alb-cre]21Mgn/J mice (Postic et al. 1999), B6.Cg-Tg[Mx1-cre]1Cgn/J mice (Kuhn et al. 1995), and C57BL/6J mice were obtained from The Jackson Laboratories (stock numbers 003574, 003556, and 000664, respectively). The mutant mice were maintained on a C57BL/6J strain background (backcrossed 10 generations), and were housed in a facility accredited by the American Association for Laboratory Animal Care (AALAC). Deletion of floxed alleles in *Mx1-Cre* mice was performed by treatment of 4-wk-old mice with 20 μ g/g polyinosinic-polycytidylic acid (polyIC) (Mikkola et al. 2003) followed by recovery (4 wk). Control mice were similarly injected with polyIC. PHx was performed on 10-wk-old mice using methods described previously (Greene and Puder 2003). The animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School.

Genotype analysis

Genotype analysis was performed by PCR using genomic DNA as the template. The *Jnk1⁺* (540 base pairs [bp]) and *Jnk1^{LoxP}* (330 bp) alleles were identified using the amplimers 5'-AGGATTTATGCCCTCTGCTTGTC-3' and 5'-GAACCACTGTTCCAATTCCATCC-3'. The *Jnk1^{LoxP}* (1100 bp) and *Jnk1^Δ* (400 bp) alleles were identified using the amplimers 5'-CCTCAGGAAGAAA GGGCTTATTTTC-3' and 5'-GAACCACTGTTCCAATTTCCATCC-3'. The *Jnk2⁺* (400 bp) and *Jnk2⁻* (270 bp) alleles were identified using the amplimers 5'-GGAGCCCGATAGTATCGA GTTACC-3', 5'-GTTAGACAATCCCAGAGGTTGTGTG-3', and 5'-CCAGCTCATTCTCCACTCATG-3'. *Cre* alleles (450 bp) were detected using the amplimers 5'-TTACTGACCGTACAC CAAATTTGCCTGC-3' and 5'-CCTGGCAGCGATCGCTATT TTCCATGAGTG-3'.

HCC assays

Carcinogen-induced HCC was studied using procedures described previously (Sakurai et al. 2008). Two-week-old male mice were treated by intraperitoneal (i.p.) injection with a single dose (25 mg/kg) of DEN (Sigma, N0258) diluted in glyceryl trioctanoate (Sigma, T9126). Control mice were injected with solvent alone. The mice were euthanized at 38 wk of age to examine tumor development. Surface tumor size and number were measured using stereomicroscopy (Maeda et al. 2005). The *Cre^{+/+}* genetic background altered the tumor burden in the DEN-induced HCC studies; more tumors were found in the *Mx1-Cre^{+/+}* genetic background than in the *Alb-Cre^{+/+}* genetic background (Figs. 2, 3). We therefore compared control

Mx1-Cre^{+/-} mice with JNK-deficient *Mx1-Cre^{+/-}* mice or control *Alb-Cre^{+/-}* mice with JNK-deficient *Alb-Cre^{+/-}* mice.

Serum analysis

Alanine transaminase (ALT) and aspartate aminotransferase (AST) activity in serum was measured using the ALT and AST Reagent kit (Pointe Scientific) with a Tecan Sapphire microplate reader (Tecan Trading AG). The serum concentration of cytokines was measured by multiplexed ELISA using a Luminex 200 instrument (Millipore).

Biochemical analysis

Immunoblot analysis was performed by probing with antibodies to activated Caspase 3 (Cell Signaling, #9661) Sprouty2 (Abcam, #ab50317), PTEN (Cell Signaling, #9198), p21 (Santa Cruz Biotechnology, #SC 6246), and α -Tubulin (Sigma, #T5168). Immunoblots were quantitated using a LiCOR Odyssey imager. The amount of total and phospho-JNK, ERK, p38 MAPK, and AKT in tissue extracts was measured using a multiplexed ELISA kit (Bio-Rad) and a Luminex 200 instrument (Millipore).

Quantitative RT-PCR assays (TaqMan) of mRNA expression were performed using a 7500 Fast Real-Time PCR machine (Applied Biosystems) with total RNA prepared from tissues with an RNeasy minikit (Qiagen). The probes were *cFos* (Mm00487425_m1), *cJun* (Mm 00495062_s1), *cMyc* (Mm00487804_m1), *Cyclin D1* (Mm00432359_m1), *Il1a* (00439621_m1), *Il1b* (Mm00434228_m1), *Il6* (Mm00446190_m1), *JunB* (Mm00492781_s1), *JunD* (Mm 00495088_s1), *p15* (Mm00483241_m1), *p21* (Mm 00432448_m1), *Pten* (Mm01212532_m1), *Socs3* (Mm00545913_s1), *Spr2* (Mm00442344_m1), *Tgfb1* (Mm03024053_m1), and *Tnf* (Mm00443258_m1) (Applied Biosystems). The relative mRNA expression was normalized by measuring the amount of *Gapdh* RNA in each sample using TaqMan assays (Applied Biosystems, 4352339E-0904021).

We prepared RNA from tissue samples using the mirVana microRNA isolation kit (Ambion) for the analysis of *miR-21* expression using TaqMan assays (Applied Biosystems, *miR-21* RT 2493). The relative *miR-21* expression was normalized by measuring the amount of *U6* RNA in each sample using TaqMan assays (Applied Biosystems, *U6* RT1973).

Analysis of liver sections

Histology was performed using tissue fixed in 10% formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 μ m) were cut and stained using hematoxylin and eosin (American Master Tech Scientific). Terminal deoxynucleotidyltransferase-mediated nick end labeling (TUNEL) staining of deparaffinized liver sections was performed using the In Situ Cell Death Detection kit Fluorescein (Roche) following antigen retrieval (Antigen Unmasking Solution, Vector Laboratories). Immunofluorescence analysis of deparaffinized liver sections was performed using antigen retrieval (Vector Laboratories); incubation (1 h) with 3% bovine serum albumin (BSA), 1% normal goat serum, and 0.4% Triton X-100 in phosphate-buffered saline (PBS); incubation (12 h) at 4°C with a biotin-linked antibody to PCNA (Zymed Laboratories, 13-3940) in PBS with 3% BSA; and detection of immune complexes with Streptavidin-conjugated Alexa fluor 633 (Invitrogen, S 21375) in PBS with 3% BSA. The liver sections were mounted on glass slides. Nuclei were stained with DAPI using Vectashield (Vector Laboratories). Fluorescence microscopy was performed using a Leica SP2 confocal microscope.

The incorporation of BrdU was examined using liver sections prepared from mice injected (i.p.) with 100 μ g/g BrdU (dissolved in saline) at 2 h prior to euthanasia. Livers were fixed in formalin, dehydrated, and embedded in paraffin, and 4- μ m sections were prepared. Deparaffinized liver sections were processed for antigen retrieval and incubated with an antibody to BrdU (Biogenex, #MU247-UC). Immune complexes were detected with a Streptavidin/Biotin-based Link-Label Detection kit (Biogenex, Super-sensitive Link label immunohistochemistry detection system) and DAB substrate (Vector Laboratories, #SK4100).

Statistical analysis

Differences between groups were examined for statistical significance using the Student's test or analysis of variance (ANOVA) with the Fisher's test. Kaplan-Meier analysis was performed using the log-rank test.

Acknowledgments

We thank Tammy Barrett, Vicky Benoit, Linda Leehy, and Jian-Hua Liu for expert technical assistance, and Kathy Gemme for administrative assistance. These studies were supported by grants from the National Institutes of Health (CA65861 and AI046629). Core facilities at the University of Massachusetts used by these studies were supported by the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) Diabetes and Endocrinology Research Center (DK32520). R.J.D. is an Investigator of the Howard Hughes Medical Institute.

References

- Behrens A, Sibilio M, Wagner EF. 1999. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. *Nat Genet* **21**: 326–329.
- Behrens A, Sibilio M, David JP, Mohle-Steinlein U, Tronche F, Schutz G, Wagner EF. 2002. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. *EMBO J* **21**: 1782–1790.
- Belgardt BF, Mauer J, Wunderlich FT, Ernst MB, Pal M, Spohn G, Bronneke HS, Brodesser S, Hampel B, Schauss AC, et al. 2010. Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. *Proc Natl Acad Sci* **107**: 6028–6033.
- Cabrita MA, Christofori G. 2008. Sprouty proteins, master-minds of receptor tyrosine kinase signaling. *Angiogenesis* **11**: 53–62.
- Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. *Nat Med* **13**: 851–856.
- Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. 2008. Elevated expression of the miR-17-92 polycistron and miR-21 in hepatitis virus-associated hepatocellular carcinoma contributes to the malignant phenotype. *Am J Pathol* **173**: 856–864.
- Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. *Science* **274**: 1379–1383.
- Das M, Jiang F, Sluss HK, Zhang C, Shokat KM, Flavell RA, Davis RJ. 2007. Suppression of p53-dependent senescence by the JNK signal transduction pathway. *Proc Natl Acad Sci* **104**: 15759–15764.

- Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ. 2009. Induction of hepatitis by JNK-mediated expression of TNF- α . *Cell* **136**: 249–260.
- Davis RJ. 2000. Signal transduction by the JNK group of MAP kinases. *Cell* **103**: 239–252.
- Eferl R, Wagner EF. 2003. AP-1: a double-edged sword in tumorigenesis. *Nat Rev Cancer* **3**: 859–868.
- Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF. 2003. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. *Cell* **112**: 181–192.
- Fausto N. 1999. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. *Semin Liver Dis* **19**: 243–252.
- Greene AK, Puder M. 2003. Partial hepatectomy in the mouse: technique and perioperative management. *J Invest Surg* **16**: 99–102.
- Greenman C, Stephens P, Smith R, Dalgleish GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. 2007. Patterns of somatic mutation in human cancer genomes. *Nature* **446**: 153–158.
- Grivennikov SI, Grenten FR, Karin M. 2010. Immunity, inflammation, and cancer. *Cell* **140**: 883–899.
- Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. 1997. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. *Nature* **386**: 296–299.
- Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. 2008. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 down-regulation. *J Clin Invest* **118**: 3943–3953.
- Jazbutyte V, Thum T. 2010. MicroRNA-21: from cancer to cardiovascular disease. *Curr Drug Targets* **11**: 926–935.
- Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. 2008. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. *Clin Cancer Res* **14**: 419–427.
- Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. *Nature* **466**: 869–873.
- Kiba T. 2002. The role of the autonomic nervous system in liver regeneration and apoptosis—recent developments. *Digestion* **66**: 79–88.
- Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. 1999. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. *Neuron* **22**: 667–676.
- Kuhn R, Schwenk F, Aguet M, Rajewsky K. 1995. Inducible gene targeting in mice. *Science* **269**: 1427–1429.
- Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. 2006. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. *J Cell Biochem* **99**: 671–678.
- Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ. 2003. JunD mediates survival signaling by the JNK signal transduction pathway. *Mol Cell* **11**: 1479–1489.
- Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, et al. 2007. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. *Blood* **110**: 1330–1333.
- Maeda S, Kamata H, Luo JL, Leffert H, Karin M. 2005. IKK β couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell* **121**: 977–990.
- Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. 1996. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. *Proc Natl Acad Sci* **93**: 12908–12913.
- Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* **133**: 647–658.
- Mikkola HK, Klintman J, Yang H, Hock H, Schlaeger TM, Fujiwara Y, Orkin SH. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. *Nature* **421**: 547–551.
- Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP. 2009. Liver stem cells and hepatocellular carcinoma. *Hepatology* **49**: 318–329.
- Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science* **317**: 121–124.
- Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* **140**: 197–208.
- Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. *J Biol Chem* **274**: 305–315.
- Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. *J Biol Chem* **270**: 7420–7426.
- Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. 2008. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* **322**: 1539–1543.
- Sabio G, Cavanagh-Kyros J, Barrett T, Jung DY, Ko HJ, Ong H, Morel C, Mora A, Reilly J, Kim JK, et al. 2010. Role of the hypothalamic–pituitary–thyroid axis in metabolic regulation by JNK1. *Genes Dev* **24**: 256–264.
- Sakurai T, Maeda S, Chang L, Karin M. 2006. Loss of hepatic NF- κ B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. *Proc Natl Acad Sci* **103**: 10544–10551.
- Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. 2008. Hepatocyte necrosis induced by oxidative stress and IL-1 α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell* **14**: 156–165.
- Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. 1999. Control of cell cycle progression by c-Jun is p53 dependent. *Genes Dev* **13**: 607–619.
- Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R, Brenner DA. 2003. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. *Hepatology* **37**: 824–832.
- Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, Hui L, Wagner EF. 2006. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. *Genes Dev* **20**: 2306–2314.
- Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Barsagi D, Jones SN, Flavell RA, Davis RJ. 2000. Requirement of

- JNK for stress-induced activation of the cytochrome c-mediated death pathway. *Science* **288**: 870–874.
- Ventura JJ, Kennedy NJ, Lamb JA, Flavell RA, Davis RJ. 2003. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. *Mol Cell Biol* **23**: 2871–2882.
- Wagner EF, Nebreda AR. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat Rev Cancer* **9**: 537–549.
- Westwick JK, Weitzel C, Leffert HL, Brenner DA. 1995. Activation of Jun kinase is an early event in hepatic regeneration. *J Clin Invest* **95**: 803–810.
- Whitmarsh AJ, Davis RJ. 2007. Role of mitogen-activated protein kinase kinase 4 in cancer. *Oncogene* **26**: 3172–3184.
- Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M, Flavell RA. 1998. Differentiation of CD4⁺ T cells to Th1 cells requires MAP kinase JNK2. *Immunity* **9**: 575–585.

The role of JNK in the development of hepatocellular carcinoma

Madhumita Das, David S. Garlick, Dale L. Greiner, et al.

Genes Dev. 2011, **25**:

Access the most recent version at doi:[10.1101/gad.1989311](https://doi.org/10.1101/gad.1989311)

**Supplemental
Material**

<http://genesdev.cshlp.org/content/suppl/2011/03/14/25.6.634.DC1>

References

This article cites 49 articles, 18 of which can be accessed free at:
<http://genesdev.cshlp.org/content/25/6/634.full.html#ref-list-1>

License

Freely available online through the Genes & Development Open Access option.

**Email Alerting
Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE